Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling.

Published

Journal Article

Genomic sequencing has driven precision-based oncology therapy; however, the genetic drivers of many malignancies remain unknown or non-targetable, so alternative approaches to the identification of therapeutic leads are necessary. Ependymomas are chemotherapy-resistant brain tumours, which, despite genomic sequencing, lack effective molecular targets. Intracranial ependymomas are segregated on the basis of anatomical location (supratentorial region or posterior fossa) and further divided into distinct molecular subgroups that reflect differences in the age of onset, gender predominance and response to therapy. The most common and aggressive subgroup, posterior fossa ependymoma group A (PF-EPN-A), occurs in young children and appears to lack recurrent somatic mutations. Conversely, posterior fossa ependymoma group B (PF-EPN-B) tumours display frequent large-scale copy number gains and losses but have favourable clinical outcomes. More than 70% of supratentorial ependymomas are defined by highly recurrent gene fusions in the NF-κB subunit gene RELA (ST-EPN-RELA), and a smaller number involve fusion of the gene encoding the transcriptional activator YAP1 (ST-EPN-YAP1). Subependymomas, a distinct histologic variant, can also be found within the supratetorial and posterior fossa compartments, and account for the majority of tumours in the molecular subgroups ST-EPN-SE and PF-EPN-SE. Here we describe mapping of active chromatin landscapes in 42 primary ependymomas in two non-overlapping primary ependymoma cohorts, with the goal of identifying essential super-enhancer-associated genes on which tumour cells depend. Enhancer regions revealed putative oncogenes, molecular targets and pathways; inhibition of these targets with small molecule inhibitors or short hairpin RNA diminished the proliferation of patient-derived neurospheres and increased survival in mouse models of ependymomas. Through profiling of transcriptional enhancers, our study provides a framework for target and drug discovery in other cancers that lack known genetic drivers and are therefore difficult to treat.

Full Text

Duke Authors

Cited Authors

  • Mack, SC; Pajtler, KW; Chavez, L; Okonechnikov, K; Bertrand, KC; Wang, X; Erkek, S; Federation, A; Song, A; Lee, C; Wang, X; McDonald, L; Morrow, JJ; Saiakhova, A; Sin-Chan, P; Wu, Q; Michaelraj, KA; Miller, TE; Hubert, CG; Ryzhova, M; Garzia, L; Donovan, L; Dombrowski, S; Factor, DC; Luu, B; Valentim, CLL; Gimple, RC; Morton, A; Kim, L; Prager, BC; Lee, JJY; Wu, X; Zuccaro, J; Thompson, Y; Holgado, BL; Reimand, J; Ke, SQ; Tropper, A; Lai, S; Vijayarajah, S; Doan, S; Mahadev, V; Miñan, AF; Gröbner, SN; Lienhard, M; Zapatka, M; Huang, Z; Aldape, KD; Carcaboso, AM; Houghton, PJ; Keir, ST; Milde, T; Witt, H; Li, Y; Li, C-J; Bian, X-W; Jones, DTW; Scott, I; Singh, SK; Huang, A; Dirks, PB; Bouffet, E; Bradner, JE; Ramaswamy, V; Jabado, N; Rutka, JT; Northcott, PA; Lupien, M; Lichter, P; Korshunov, A; Scacheri, PC; Pfister, SM; Kool, M; Taylor, MD; Rich, JN

Published Date

  • January 2018

Published In

Volume / Issue

  • 553 / 7686

Start / End Page

  • 101 - 105

PubMed ID

  • 29258295

Pubmed Central ID

  • 29258295

Electronic International Standard Serial Number (EISSN)

  • 1476-4687

International Standard Serial Number (ISSN)

  • 0028-0836

Digital Object Identifier (DOI)

  • 10.1038/nature25169

Language

  • eng